Montenegro
Tuberculosis profile
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.19 (0.13–0.25)
Mortality (HIV+TB only) <0.01 (0–<0.01) 0.02 (0–0.17)
Prevalence  (includes HIV+TB) 0.15 (0.065–0.28) 25 (10–45)
Incidence  (includes HIV+TB) 0.11 (0.1–0.13) 18 (16–20)
Incidence (HIV+TB only) <0.01 (0–<0.01) 0.05 (0–0.54)
Case detection, all forms (%) 87 (78–97)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 45 (48) Relapse 4 (31)
Smear-negative 33 (35) Treatment after failure 0 (0)
Smear-unknown / not done 3 (3) Treatment after default 0 (0)
Extrapulmonary 13 (14) Other 9 (69)
Other 0 (0)      
Total new 94   Total retreatment 13  
           
Other (history unknown) 0        
Total new and relapse 98   Total cases notified 107  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.8 1.8 0.6
Age < 15 0 0 0
Laboratories 2012
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 8.1
Drug susceptibility testing (per 5 million population) 8.1
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 86   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 86  
Retreatment 83  
TB/HIV 2012 Number (%)
TB patients with known HIV status 82 (77)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0 (0–6.2) 0 (0–52)
MDR-TB cases among notified pulmonary
TB cases
0 (0–5) 0 (0–7)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 58 (98%) 5 (38%) 63
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 73%
% Funded internationally  
% Unfunded 27%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data